One-Patient trial tests keytruda for rare ovarian cancer
NCT ID NCT05368207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Because only one person took part, the results are very limited and cannot be generalized.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda), a drug that helps the immune system fight cancer
What this could lead to
If it works, this could point toward a treatment option for a rare and aggressive ovarian cancer.
What could go wrong
This is a single-patient study with no control group, so results may not apply to others. The drug may not prevent cancer from returning and can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada